Bioactive Anti-Thrombotic Modification of Decellularized Matrix for Vascular Applications

Jeremy J. Glynn, Monica Hinds

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The decellularized matrix derived from porcine small intestinal submucosa (SIS) is a widely used biomaterial being investigated for numerous applications. Currently, thrombus deposition and neointimal hyperplasia have limited the use of SIS in some vascular applications. To limit these detrimental processes, this work applies bioactive, endothelial-inspired properties to the material. SIS is modified with the endothelial cell membrane protein thrombomodulin and the glycosaminoglycan heparin to facilitate protein C activation and anticoagulant activity, respectively. Modifying SIS with thrombomodulin alone enables robust activated protein C (APC) generation, and thrombomodulin activity is maintained after prolonged exposure to fluid shear and blood plasma. Heparin-modified SIS has a potent anticoagulant activity. When both modifications are applied sequentially, SIS modified first with thrombomodulin then with heparin retains the full activity of each individual modification. Tubular SIS devices are connected to a baboon arteriovenous shunt to quantify thrombus deposition on these materials. After being exposed to flowing whole blood for 60 min, SIS devices modified first with thrombomodulin then with heparin have significantly less platelet accumulation compared to unmodified SIS devices. These studies demonstrate that modifying SIS with thrombomodulin and heparin confers APC generation and anticoagulant activity that results in reduced thrombogenesis.

Original languageEnglish (US)
Pages (from-to)1439-1446
Number of pages8
JournalAdvanced healthcare materials
Volume5
Issue number12
DOIs
StatePublished - Jun 22 2016

Fingerprint

Thrombomodulin
Blood Vessels
Heparin
Proteins
Protein C
Anticoagulants
Blood
Equipment and Supplies
Thrombosis
Endothelial cells
Cell membranes
Platelets
Biomaterials
Papio
Biocompatible Materials
Glycosaminoglycans
Chemical activation
Hyperplasia
Membrane Proteins
Plasmas

Keywords

  • coagulation
  • decellularized biomaterial
  • heparin
  • platelets
  • thrombomodulin

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials
  • Pharmaceutical Science

Cite this

Bioactive Anti-Thrombotic Modification of Decellularized Matrix for Vascular Applications. / Glynn, Jeremy J.; Hinds, Monica.

In: Advanced healthcare materials, Vol. 5, No. 12, 22.06.2016, p. 1439-1446.

Research output: Contribution to journalArticle

@article{703d7d3847e646fbabb12e2126c2d42a,
title = "Bioactive Anti-Thrombotic Modification of Decellularized Matrix for Vascular Applications",
abstract = "The decellularized matrix derived from porcine small intestinal submucosa (SIS) is a widely used biomaterial being investigated for numerous applications. Currently, thrombus deposition and neointimal hyperplasia have limited the use of SIS in some vascular applications. To limit these detrimental processes, this work applies bioactive, endothelial-inspired properties to the material. SIS is modified with the endothelial cell membrane protein thrombomodulin and the glycosaminoglycan heparin to facilitate protein C activation and anticoagulant activity, respectively. Modifying SIS with thrombomodulin alone enables robust activated protein C (APC) generation, and thrombomodulin activity is maintained after prolonged exposure to fluid shear and blood plasma. Heparin-modified SIS has a potent anticoagulant activity. When both modifications are applied sequentially, SIS modified first with thrombomodulin then with heparin retains the full activity of each individual modification. Tubular SIS devices are connected to a baboon arteriovenous shunt to quantify thrombus deposition on these materials. After being exposed to flowing whole blood for 60 min, SIS devices modified first with thrombomodulin then with heparin have significantly less platelet accumulation compared to unmodified SIS devices. These studies demonstrate that modifying SIS with thrombomodulin and heparin confers APC generation and anticoagulant activity that results in reduced thrombogenesis.",
keywords = "coagulation, decellularized biomaterial, heparin, platelets, thrombomodulin",
author = "Glynn, {Jeremy J.} and Monica Hinds",
year = "2016",
month = "6",
day = "22",
doi = "10.1002/adhm.201600020",
language = "English (US)",
volume = "5",
pages = "1439--1446",
journal = "Advanced healthcare materials",
issn = "2192-2640",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Bioactive Anti-Thrombotic Modification of Decellularized Matrix for Vascular Applications

AU - Glynn, Jeremy J.

AU - Hinds, Monica

PY - 2016/6/22

Y1 - 2016/6/22

N2 - The decellularized matrix derived from porcine small intestinal submucosa (SIS) is a widely used biomaterial being investigated for numerous applications. Currently, thrombus deposition and neointimal hyperplasia have limited the use of SIS in some vascular applications. To limit these detrimental processes, this work applies bioactive, endothelial-inspired properties to the material. SIS is modified with the endothelial cell membrane protein thrombomodulin and the glycosaminoglycan heparin to facilitate protein C activation and anticoagulant activity, respectively. Modifying SIS with thrombomodulin alone enables robust activated protein C (APC) generation, and thrombomodulin activity is maintained after prolonged exposure to fluid shear and blood plasma. Heparin-modified SIS has a potent anticoagulant activity. When both modifications are applied sequentially, SIS modified first with thrombomodulin then with heparin retains the full activity of each individual modification. Tubular SIS devices are connected to a baboon arteriovenous shunt to quantify thrombus deposition on these materials. After being exposed to flowing whole blood for 60 min, SIS devices modified first with thrombomodulin then with heparin have significantly less platelet accumulation compared to unmodified SIS devices. These studies demonstrate that modifying SIS with thrombomodulin and heparin confers APC generation and anticoagulant activity that results in reduced thrombogenesis.

AB - The decellularized matrix derived from porcine small intestinal submucosa (SIS) is a widely used biomaterial being investigated for numerous applications. Currently, thrombus deposition and neointimal hyperplasia have limited the use of SIS in some vascular applications. To limit these detrimental processes, this work applies bioactive, endothelial-inspired properties to the material. SIS is modified with the endothelial cell membrane protein thrombomodulin and the glycosaminoglycan heparin to facilitate protein C activation and anticoagulant activity, respectively. Modifying SIS with thrombomodulin alone enables robust activated protein C (APC) generation, and thrombomodulin activity is maintained after prolonged exposure to fluid shear and blood plasma. Heparin-modified SIS has a potent anticoagulant activity. When both modifications are applied sequentially, SIS modified first with thrombomodulin then with heparin retains the full activity of each individual modification. Tubular SIS devices are connected to a baboon arteriovenous shunt to quantify thrombus deposition on these materials. After being exposed to flowing whole blood for 60 min, SIS devices modified first with thrombomodulin then with heparin have significantly less platelet accumulation compared to unmodified SIS devices. These studies demonstrate that modifying SIS with thrombomodulin and heparin confers APC generation and anticoagulant activity that results in reduced thrombogenesis.

KW - coagulation

KW - decellularized biomaterial

KW - heparin

KW - platelets

KW - thrombomodulin

UR - http://www.scopus.com/inward/record.url?scp=84976573043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976573043&partnerID=8YFLogxK

U2 - 10.1002/adhm.201600020

DO - 10.1002/adhm.201600020

M3 - Article

C2 - 27072858

AN - SCOPUS:84976573043

VL - 5

SP - 1439

EP - 1446

JO - Advanced healthcare materials

JF - Advanced healthcare materials

SN - 2192-2640

IS - 12

ER -